TXMD stock: buy or sell?

TXMD stock price: $3.71 0.00% At close on September 20th, 2019

Updated on:
September 20th, 2019


Shares of TherapeuticsMD ended today at $3.71 and stayed stable a neutral 0.00%. On Monday TXMD boosted a super good 7.32%.

TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Should I buy TXMD stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to choose your own trading strategy that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, TherapeuticsMD stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean TXMD will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is TherapeuticsMD stock a buy?

Financial institutions and banks post stock ratings everyday. At Stocks2.com, we detected 9 ratings published for TXMD stock in the last month.

The general sentiment of these ratings is bullish for TXMD stock, with 7 positive ratings.
Is TXMD a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-7Cantor Fitzgeraldn/aOverweight
2019-8-12Noble Financialn/aBuy
2019-7-15Jefferies Financial Groupn/an/a
2019-6-12Cantor Fitzgeraldn/aOverweight
2019-6-11JPMorgan Chase & Co.n/aOverweight
2019-5-7Jefferies Financial Groupn/aHold

TXMD stock analysis

Daily outlook

TherapeuticsMD stayed steady a neutral 0.00% and closed at $3.71.

TherapeuticsMD stayed stable a neutral 0.00% and closed at $3.71. From a daily perspective, TXMD is in a short term uptrend after plotting its last bottom ($2.73, on Sep/4) higher than the previous bottom, and its last top ($3.98, yesterday) also over the previous top. Now trading in between its last bottom and last top TXMD might consolidate in a plain range, waiting to break out over $3.98 or down under $2.73. Since price and SMA100d lines crossed up on September/9, TXMD climbed $0.84 (29.27%).

TXMD stock chart (daily)

Weekly outlook

TherapeuticsMD ended this week at $3.71 and climbed a dazzling 8.48%. By mid August TXMD collapsed a scary -8.39% in just one week.

TXMD stock chart (weekly)

TXMD stock price history

TXMD IPO was on October 5th, 2017 at $5.15 per share1. Since then, TXMD stock declined a -28.00%, with a yearly average of -28.00%.

1: Adjusted price after possible price splits or reverse-splits.

TXMD stock historical price chart

TXMD stock reached 52-week highs at $6.94, and all-time highs 2018-06-08 with a price of 7.66.

TXMD stock price target is $8.70

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We have 9 price targets for TherapeuticsMD stock published in the last 30 days:
TXMD stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-7Cantor FitzgeraldReiterates$13.00$2.05-84.2%
2019-8-12Noble FinancialReiteratesn/a$13.00-
2019-7-15Jefferies Financial GroupLowers Target$4.00$3.00-25%
2019-6-12Cantor FitzgeraldReiterates$27.00$13.00-51.9%
2019-6-11JPMorgan Chase & Co.Lowers Target$8.00$6.00-25%
2019-5-7Jefferies Financial GroupLowers Target$5.00$4.00-20%
2019-2-11OppenheimerSet Price Targetn/a$14.00-
(in average)$12.20$8.70-29.0%
Moving in a range from $14.00 and $2.05, the price prediction for TXMD stock is $8.70. In average, analysts' outlook on TXMD price target is negative, downsizing the target by a -29.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, TherapeuticsMD matched the estimates of the experts and reported an EPS of $-0.17 per share. As soon as we get its actual EPS from the earnings report, we will extend this review.
TXMD earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, TherapeuticsMD annual sales declined an awful -4.04% to $16.10 M USD from $16.78 marked in 2017. Improving that, its earnings margin (compared to revenues) plunged to -823.73%, that is $-132.62 million.

TXMD annual Sales and Income evolution
2013$8.78 M-$-28.42 M-323.7%-
2014$15 M71.14%$-54.22 M-360.8%90.77%
2015$20 M34.05%$-85.08 M-422.4%56.92%
2016$19 M-3.90%$-89.88 M-464.3%5.64%
2017$17 M-13.32%$-76.93 M-458.5%-14.41%
2018$16 M-4.04%$-132.62 M-823.7%72.40%

Quarterly financial results

TherapeuticsMD posted $5.09 million in revenues for 2018-Q4, a 46.52% improvement compared to previous quarter. Reported quarter income marked $-39.39 million with a profit margin of -773.96%. Profit margin skyrocketed a 251.08% compared to previous quarter when profit margin was -1,025.04%. When comparing sales to same quarter last year, TherapeuticsMD sales marked an exceptional growth and boosted a 23.41%.
TXMD quarterly Sales and Income evolution
2017-Q1$4 M-$-21.16 M-530.3%-
2017-Q2$4 M6.52%$-19.68 M-463.1%-6.99%
2017-Q3$4 M3.94%$-14.66 M-332.0%-25.48%
2017-Q4$4 M-6.64%$-21.43 M-519.5%46.12%
2018-Q1$4 M-8.51%$-24.40 M-646.7%13.88%
2018-Q2$4 M-0.28%$-33.22 M-882.8%36.13%
2018-Q3$3 M-7.69%$-35.61 M-1025.0%7.18%
2018-Q4$5 M46.52%$-39.39 M-774.0%10.63%

TherapeuticsMD ownership

When you are planning to invest in a company, it's always worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For TherapeuticsMD, 17.76% of all outstanding shares are owned by its staff.

In case of TherapeuticsMD stock, 78.61% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for TXMD stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to TherapeuticsMD:

Market cap$894.9 M$106.1 B$70.0 M$443.8 M$541.9 M
Total shares241.2 M1,480.0 M59.3 M33.9 M40.4 M
Float shares198.7 M1,480.0 M31.0 M15.8 M26.6 M
  - Institutional holdings (%)78.6%71.9%54.2%121.2%86.6%
  - Insider holdings (%)17.8%0.1%1.3%2.1%28.2%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

TXMD summary

Friday, September 20th, 2019
Day range$3.39 - $3.77
Previous close$3.71
Session gain0.00%
Average true range$0.25
50d mov avg$2.73
100d mov avg$2.89
200d mov avg$3.89
Daily patternlt06a
Weekly pattern lt03a

TherapeuticsMD performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For TherapeuticsMD, the comparison is made against AbbVie, Agile Therapeutics, AMAG Pharmaceuticals, Lannett and Pfizer.
AGRXAgile Therapeutic...-18.62%-20.27%247.06%
AMAGAMAG Pharmaceutic...45.93%7.65%-36.61%

TherapeuticsMD competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for TherapeuticsMD. We chose 5 companies as TherapeuticsMD competitors as they are in the same industry or have similar market objectives.